Critical appraisal of the SHARP trial: the results may be dull

Area of Science:

• Cardiovascular medicine
• Nephrology
• Pharmacology

Background:

• The SHARP trial investigated the efficacy of lipid-lowering therapy in patients with chronic kidney disease.
• Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) ± ezetimibe were evaluated in this population.
• Prior to this analysis, the SHARP trial influenced clinical practice regarding lipid management in kidney disease.

Purpose of the Study:

• To critically analyze the SHARP trial and its implications for clinical practice.
• To evaluate the evidence supporting the use of statins ± ezetimibe in patients with chronic kidney disease.
• To provide a nuanced perspective on the benefits of lipid-lowering therapy in this patient group.

Main Methods:

• Critical appraisal of the SHARP trial.
• Review of associated documents, including FDA reviews and the SHARP protocol.
• Examination of pre-SHARP trial background reviews and studies for contextual understanding.

Main Results:

• The critical analysis identified significant criticisms of the SHARP trial's methodology and findings.
• Questionable clinical benefit was suggested for lipid-lowering therapy in patients with chronic kidney disease based on the SHARP trial.
• The results indicate a need for careful consideration of statin ± ezetimibe use in this population.

Conclusions:

• Clinicians should exercise caution when prescribing statins ± ezetimibe to all patients with chronic kidney disease.
• Broad prescription of these agents should be limited unless specific indications, such as pre-existing cardiovascular disease, are present.
• The findings advocate for a more selective approach to lipid management in dialysis and nondialysis patients with chronic kidney disease.